All In Biotech

Free tool

FAERS Monitor: Alphagan P

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021770 or its brand name (Alphagan P, Brimonidine Tartrate). Reports on generic versions are filed under their own applications.

Reports

9,475

Serious

4,593

48% of reports

Hospitalization

1,856

Death reported

491

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye pain602
  • eye irritation599
  • drug ineffective591
  • ocular hyperaemia574
  • fatigue464
  • vision blurred458
  • intraocular pressure increased397
  • off label use395
  • dizziness374
  • headache374
  • diarrhoea300
  • dyspnoea298
  • death282
  • visual impairment275
  • asthenia264

Reports by year received

View as table
YearReports
200440
200556
200655
200774
200859
2009126
201085
2011127
2012232
2013255
2014406
2015654
2016754
2017721
2018638
2019691
2020837
2021547
2022576
2023598
2024619
2025633
2026692

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,684 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intraocular pressure increasedSignal39771.164.526,548
ocular hyperaemiaSignal57427.225.114,297
eye painSignal60223.922.113,098
eye irritationSignal59923.321.612,684
vision blurredSignal4587.46.82,548
visual impairmentSignal2754.94.4862
dizziness3741.71.5101
asthenia2641.61.453
headache3741.31.230
fatigue4641.31.238
dyspnoea2981.21.07
diarrhoea3001.00.90
off label use3951.00.90
drug ineffective5911.00.90
death2820.70.630

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.